{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:36:30Z","timestamp":1779910590701,"version":"3.53.1"},"reference-count":125,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173677"],"award-info":[{"award-number":["82173677"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M711938"],"award-info":[{"award-number":["2022M711938"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019-104176RB-I00\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["PID2019-104176RB-I00\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.apsb.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T11:54:25Z","timestamp":1692014065000},"page":"4715-4732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Emerging drug design strategies in anti-influenza drug discovery"],"prefix":"10.1016","volume":"13","author":[{"given":"Chuanfeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lide","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5574-5590","authenticated-orcid":false,"given":"Guanyu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edeildo","family":"Ferreira da Silva-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-7882","authenticated-orcid":false,"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-6640","authenticated-orcid":false,"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7168-613X","authenticated-orcid":false,"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2023.08.010_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41579-021-00542-7","article-title":"Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract","volume":"19","author":"Flerlage","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2023.08.010_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008109","article-title":"Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics","volume":"15","author":"Gostic","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2023.08.010_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s12276-021-00603-0","article-title":"The evolution and future of influenza pandemic preparedness","volume":"53","author":"Harrington","year":"2021","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.apsb.2023.08.010_bib4","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3390\/v14112452","article-title":"Antiviral potential of natural resources against influenza virus infections","volume":"14","author":"Eichberg","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2023.08.010_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17527","article-title":"Comparison of estimated excess deaths in New York City during the COVID-19 and 1918 influenza pandemics","volume":"3","author":"Faust","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.apsb.2023.08.010_bib6","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1002\/jmv.27052","article-title":"Informing the global COVID-19 response by estimating excess deaths in Italy during the COVID-19 and 1918 influenza pandemics","volume":"93","author":"Gillezeau","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.apsb.2023.08.010_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-biochem-072820-100645","article-title":"Influenza virus RNA-dependent RNA polymerase and the host transcriptional apparatus","volume":"90","author":"Krischuns","year":"2021","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apsb.2023.08.010_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/vim.2019.0032","article-title":"Role of the innate cytokine storm induced by the influenza A virus","volume":"32","author":"Gu","year":"2019","journal-title":"Viral Immunol"},{"key":"10.1016\/j.apsb.2023.08.010_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.tim.2018.05.013","article-title":"Influenza virus","volume":"26","author":"Hutchinson","year":"2018","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.apsb.2023.08.010_bib10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tim.2022.09.015","article-title":"A structural understanding of influenza virus genome replication","volume":"31","author":"Zhu","year":"2023","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.apsb.2023.08.010_bib11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cmi.2016.07.007","article-title":"Functional balance between neuraminidase and haemagglutinin in influenza viruses","volume":"22","author":"Gaymard","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.apsb.2023.08.010_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.semcdb.2016.07.007","article-title":"Mechanisms of influenza viral membrane fusion","volume":"60","author":"Blijleven","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.apsb.2023.08.010_bib13","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.1016\/j.vaccine.2012.04.085","article-title":"Nuclear import of the influenza A virus transcriptional machinery","volume":"30","author":"Hutchinson","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2023.08.010_bib14","doi-asserted-by":"crossref","first-page":"a038398","DOI":"10.1101\/cshperspect.a038398","article-title":"Structure and function of the influenza virus transcription and replication machinery","volume":"10","author":"Fodor","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.apsb.2023.08.010_bib15","doi-asserted-by":"crossref","first-page":"16557","DOI":"10.1073\/pnas.2002828117","article-title":"Dissecting the mechanism of signaling-triggered nuclear export of newly synthesized influenza virus ribonucleoprotein complexes","volume":"117","author":"Schreiber","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2023.08.010_bib16","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1038\/s41467-020-18108-1","article-title":"Selective flexible packaging pathways of the segmented genome of influenza A virus","volume":"11","author":"Haralampiev","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.010_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2009.05.010","article-title":"Influenza virus morphogenesis and budding","volume":"143","author":"Nayak","year":"2009","journal-title":"Virus Res"},{"key":"10.1016\/j.apsb.2023.08.010_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.chom.2010.05.008","article-title":"Cellular networks involved in the influenza virus life cycle","volume":"7","author":"Watanabe","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.apsb.2023.08.010_bib19","first-page":"1","article-title":"Emerging antiviral therapies and drugs for the treatment of influenza","author":"Wang","year":"2022","journal-title":"Expet Opin Emerg Drugs"},{"key":"10.1016\/j.apsb.2023.08.010_bib20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7150\/thno.17071","article-title":"Progress of small molecular inhibitors in the development of anti-influenza virus agents","volume":"7","author":"Wu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2023.08.010_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-981-16-0267-2_8","article-title":"Anti-influenza drug discovery and development: targeting the virus and its host by all possible means","volume":"1322","author":"Terrier","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.apsb.2023.08.010_bib22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/13543784.2021.1994944","article-title":"Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects","volume":"30","author":"Hu","year":"2021","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.apsb.2023.08.010_bib23","first-page":"62","article-title":"PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor","volume":"S1995-820X","author":"Luo","year":"2023","journal-title":"Virol Sin"},{"key":"10.1016\/j.apsb.2023.08.010_bib24","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.apsb.2021.11.018","article-title":"Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins","volume":"12","author":"Hou","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.08.010_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.apsb.2015.07.006","article-title":"New small-molecule drug design strategies for fighting resistant influenza A","volume":"5","author":"Shen","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.08.010_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coviro.2014.04.009","article-title":"The epidemiology and spread of drug resistant human influenza viruses","volume":"8","author":"Hurt","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.apsb.2023.08.010_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/acs.jcim.5b00331","article-title":"H274Y's Effect on oseltamivir resistance: what happens before the drug enters the binding site","volume":"56","author":"Yusuf","year":"2016","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2023.08.010_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105369","article-title":"Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir","volume":"204","author":"Jones","year":"2022","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2023.08.010_bib29","first-page":"21","article-title":"Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y\/G147R substitution, Japan, March 2016","author":"Takashita","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.apsb.2023.08.010_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx105","article-title":"A review of clinical influenza A and B infections with reduced susceptibility to both oseltamivir and zanamivir","volume":"4","author":"Abed","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.apsb.2023.08.010_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.antiviral.2007.12.006","article-title":"Adamantane resistance in circulating human influenza A viruses from Alberta, Canada (1970\u20132007)","volume":"79","author":"Pabbaraju","year":"2008","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2023.08.010_bib32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/v14040841","article-title":"Lethal mutagenesis of RNA viruses and approved drugs with antiviral mutagenic activity","volume":"14","author":"Hadj Hassine","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2023.08.010_bib33","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1039\/D0CS01084G","article-title":"Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses","volume":"50","author":"Ma","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2023.08.010_bib34","first-page":"77","article-title":"Virus population dynamics, fitness variations and the control of viral disease: an update","volume":"57","author":"Domingo","year":"2001","journal-title":"Prog Drug Res"},{"key":"10.1016\/j.apsb.2023.08.010_bib35","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1073\/pnas.1113300109","article-title":"Viral reassortment as an information exchange between viral segments","volume":"109","author":"Greenbaum","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2023.08.010_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012244","article-title":"Evolution of influenza viruses-drug resistance, treatment options, and prospects","volume":"23","author":"Smyk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.08.010_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12985-017-0918-y","article-title":"Towards a universal influenza vaccine: different approaches for one goal","volume":"15","author":"Sautto","year":"2018","journal-title":"Virol J"},{"key":"10.1016\/j.apsb.2023.08.010_bib38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/v13040667","article-title":"Broad-spectrum antiviral strategies and nucleoside analogues","volume":"13","author":"Robert J","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2023.08.010_bib39","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.drudis.2020.06.023","article-title":"The rise of molecular simulations in fragment-based drug design (FBDD): an overview","volume":"25","author":"Bissaro","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2023.08.010_bib40","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2174\/1568026621666210804115700","article-title":"Perspectives on fragment-based drug discovery: a strategy applicable to diverse targets","volume":"21","author":"Li","year":"2021","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib41","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1021\/acs.jmedchem.6b00628","article-title":"Fragment-based identification of influenza endonuclease inhibitors","volume":"59","author":"Credille","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib42","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1021\/cb400400j","article-title":"Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors","volume":"8","author":"Bauman","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2023.08.010_bib43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1021\/acs.jmedchem.2c00857","article-title":"Identification of N- and C-3-modified laudanosoline derivatives as novel influenza PAN endonuclease inhibitors","volume":"66","author":"Liao","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104780","article-title":"Put a cork in it: plugging the M2 viral ion channel to sink influenza","volume":"178","author":"Jalily","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2023.08.010_bib45","doi-asserted-by":"crossref","first-page":"17987","DOI":"10.1021\/ja508461m","article-title":"Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel","volume":"136","author":"Wu","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2023.08.010_bib46","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/acs.jmedchem.5b01910","article-title":"Discovery of highly potent inhibitors targeting the predominant drug-resistant S31N mutant of the influenza A virus M2 proton channel","volume":"59","author":"Li","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib47","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1021\/acs.jmedchem.6b01852","article-title":"Expeditious lead optimization of isoxazole-containing influenza A virus M2-S31N inhibitors using the suzuki-miyaura cross-coupling reaction","volume":"60","author":"Li","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib48","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/acs.jmedchem.7b01536","article-title":"In\u00a0vitro pharmacokinetic optimizations of AM2-S31N channel blockers led to the discovery of slow-binding inhibitors with potent antiviral activity against drug-resistant influenza A viruses","volume":"61","author":"Wang","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib49","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1080\/22221751.2021.1972769","article-title":"Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with in\u00a0vivo antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses","volume":"10","author":"C\u00e1ceres","year":"2021","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.apsb.2023.08.010_bib50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2017.01.006","article-title":"An M2-V27A channel blocker demonstrates potent in\u00a0vitro and in\u00a0vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses","volume":"140","author":"Hu","year":"2017","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2023.08.010_bib51","doi-asserted-by":"crossref","first-page":"8066","DOI":"10.1021\/ja900063s","article-title":"Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus","volume":"131","author":"Wang","year":"2009","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2023.08.010_bib52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2017.06.019","article-title":"Covalent inhibitors design and discovery","volume":"138","author":"De Cesco","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib53","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1039\/C7CS00220C","article-title":"Structure-based design of targeted covalent inhibitors","volume":"47","author":"Lonsdale","year":"2018","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2023.08.010_bib54","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and re-Emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib55","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1039\/D0MD00154F","article-title":"Covalent inhibitors: a rational approach to drug discovery","volume":"11","author":"Sutanto","year":"2020","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib56","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/ncomms2487","article-title":"Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors","volume":"4","author":"Vavricka","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.010_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1232552","article-title":"Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity","volume":"340","author":"Kim","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.08.010_bib58","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1021\/acs.jmedchem.7b01467","article-title":"Structural and functional analysis of anti-influenza activity of 4-, 7-, 8- and 9-deoxygenated 2,3-difluoro-N-acetylneuraminic acid derivatives","volume":"61","author":"McKimm-Breschkin","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib59","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential impact of the multi-target drug approach in the treatment of some complex diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.apsb.2023.08.010_bib60","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/cncr.34642","article-title":"Association of polypharmacy and potential drug\u2013drug interactions with adverse treatment outcomes in older adults with advanced cancer","volume":"129","author":"Mohamed","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.apsb.2023.08.010_bib61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejmech.2017.05.016","article-title":"Designing multi-targeted agents: an emerging anticancer drug discovery paradigm","volume":"136","author":"Fu","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib62","doi-asserted-by":"crossref","first-page":"8493","DOI":"10.1021\/jm3009844","article-title":"Enhanced anti-influenza agents conjugated with anti-inflammatory activity","volume":"55","author":"Liu","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib63","doi-asserted-by":"crossref","first-page":"17403","DOI":"10.1021\/acs.jmedchem.1c01531","article-title":"Zanamivir-cholesterol conjugate: a long-acting neuraminidase inhibitor with potent efficacy against drug-resistant influenza viruses","volume":"64","author":"Lv","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2023.08.010_bib65","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2023.08.010_bib66","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2023.08.010_bib67","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tips.2020.04.005","article-title":"Emerging new concepts of degrader technologies","volume":"41","author":"Ding","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2023.08.010_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib69","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2023.08.010_bib70","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/1871520620666200410082652","article-title":"Targeted protein degradation: an emerging therapeutic strategy in cancer","volume":"21","author":"Barghout","year":"2021","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: an effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2023.08.010_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2022.100030","article-title":"Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus","volume":"1","author":"Xu","year":"2022","journal-title":"Cell Insight"},{"key":"10.1016\/j.apsb.2023.08.010_bib73","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1021\/acs.jmedchem.1c02013","article-title":"Discovery of pentacyclic triterpenoid PROTACs as a class of effective hemagglutinin protein degraders","volume":"65","author":"Li","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib74","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41467-022-29690-x","article-title":"An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.010_bib75","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41587-022-01381-4","article-title":"Generation of a live attenuated influenza A vaccine by proteolysis targeting","volume":"40","author":"Si","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.08.010_bib76","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature00767","article-title":"Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL","volume":"417","author":"Hon","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.08.010_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201700247","article-title":"PROTACs: an emerging targeting technique for protein degradation in drug discovery","volume":"40","author":"Gu","year":"2018","journal-title":"Bioessays"},{"key":"10.1016\/j.apsb.2023.08.010_bib78","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1021\/cb4004942","article-title":"Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators","volume":"8","author":"Jakobsche","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2023.08.010_bib79","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nchembio.477","article-title":"Grand challenge commentary: synthetic immunology to engineer human immunity","volume":"6","author":"Spiegel","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2023.08.010_bib80","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1039\/D0MD00337A","article-title":"Synthesis and biological evaluation of a monocyclic Fc-binding antibody-recruiting molecule for cancer immunotherapy","volume":"12","author":"Sasaki","year":"2021","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib81","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1038\/s41467-021-25400-1","article-title":"Author correction: hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity","volume":"12","author":"Schrand","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.010_bib82","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1002\/anie.201510866","article-title":"Re-engineering the immune response to metastatic cancer: antibody-recruiting small molecules targeting the urokinase receptor","volume":"55","author":"Rullo","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2023.08.010_bib83","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.chembiol.2018.05.019","article-title":"Synthetic immunotherapeutics against gram-negative pathogens","volume":"25","author":"Feigman","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2023.08.010_bib84","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrd.2016.173","article-title":"Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection","volume":"15","author":"Ferrari","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2023.08.010_bib85","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1039\/C4SC00484A","article-title":"Illuminating HIV gp120-ligand recognition through computationally-driven optimization of antibody-recruiting molecules","volume":"5","author":"Parker","year":"2014","journal-title":"Chem Sci"},{"key":"10.1016\/j.apsb.2023.08.010_bib86","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1038\/s41467-020-19386-5","article-title":"A universal dual mechanism immunotherapy for the treatment of influenza virus infections","volume":"11","author":"Liu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.010_bib87","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1021\/acs.bioconjchem.1c00255","article-title":"Design of neuraminidase-targeted imaging and therapeutic agents for the diagnosis and treatment of influenza virus infections","volume":"32","author":"Liu","year":"2021","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib88","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1021\/acs.bioconjchem.9b00526","article-title":"Multivalent cluster nanomolecules for inhibiting protein-protein interactions","volume":"30","author":"Qian","year":"2019","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib89","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/cmdc.201700722","article-title":"Design, synthesis, and in\u00a0vitro evaluation of multivalent drug linkers for high-drug-load antibody-drug conjugates","volume":"13","author":"Chen","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2023.08.010_bib90","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1039\/c3cs60089k","article-title":"Bridging lectin binding sites by multivalent carbohydrates","volume":"42","author":"Wittmann","year":"2013","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2023.08.010_bib91","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/35001095","article-title":"Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands","volume":"403","author":"Kitov","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.08.010_bib92","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1021\/acsnano.7b08479","article-title":"Quantitative prediction of multivalent ligand-receptor binding affinities for influenza, cholera, and anthrax inhibition","volume":"12","author":"Liese","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2023.08.010_bib93","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1021\/jacs.8b09198","article-title":"Multivalent ligand binding to cell membrane antigens: defining the interplay of affinity, valency, and expression density","volume":"141","author":"Csizmar","year":"2019","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2023.08.010_bib94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.12.010","article-title":"Structure-activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid","volume":"139","author":"Mart\u00ednez-Gualda","year":"2017","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2023.08.010_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202007214","article-title":"A dynamic, supramolecular view on the multivalent interaction between influenza virus and host cell","volume":"17","author":"Overeem","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.apsb.2023.08.010_bib96","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1021\/acsami.0c15644","article-title":"Rationally designed multivalent aptamers targeting cell surface for biomedical applications","volume":"13","author":"Lin","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2023.08.010_bib97","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41598-020-57608-4","article-title":"Antiviral potential of 3\u2032-sialyllactose- and 6\u2032-sialyllactose-conjugated dendritic polymers against human and avian influenza viruses","volume":"10","author":"G\u00fcnther","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2023.08.010_bib98","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.biomaterials.2015.11.034","article-title":"Pentacyclic triterpenes grafted on CD cores to interfere with influenza virus entry: a dramatic multivalent effect","volume":"78","author":"Xiao","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2023.08.010_bib99","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1021\/ja5114084","article-title":"Size dependence of steric shielding and multivalency effects for globular binding inhibitors","volume":"137","author":"Vonnemann","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2023.08.010_bib100","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1039\/C5OB01405K","article-title":"Emerging trends in enzyme inhibition by multivalent nanoconstructs","volume":"13","author":"Kanfar","year":"2015","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib101","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001433","article-title":"Broad-spectrum antiviral agents based on multivalent inhibitors of viral infectivity","volume":"10","author":"Zelikin","year":"2021","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2023.08.010_bib102","doi-asserted-by":"crossref","first-page":"15662","DOI":"10.1002\/ange.202004832","article-title":"Topology-matching design of an influenza-neutralizing spiky nanoparticle-based inhibitor with a dual mode of action","volume":"132","author":"Nie","year":"2020","journal-title":"Angew Chem Weinheim Bergstr Ger"},{"key":"10.1016\/j.apsb.2023.08.010_bib103","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd3803","article-title":"Heteromultivalent topology-matched nanostructures as potent and broad-spectrum influenza A virus inhibitors","volume":"7","author":"Nie","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2023.08.010_bib104","doi-asserted-by":"crossref","first-page":"12417","DOI":"10.1002\/anie.202006145","article-title":"Adaptive flexible sialylated nanogels as highly potent influenza a virus inhibitors","volume":"59","author":"Bhatia","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2023.08.010_bib105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41565-020-0660-2","article-title":"Phage capsid nanoparticles with defined ligand arrangement block influenza virus entry","volume":"15","author":"Lauster","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2023.08.010_bib106","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2020.8645","article-title":"Research and development costs of new drugs","volume":"324","author":"Dominguez","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2023.08.010_bib107","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd1382","article-title":"Key factors in the rising cost of new drug\u00a0discovery and development","volume":"3","author":"Dickson","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2023.08.010_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.106671","article-title":"Computational drug repurposing by exploiting large-scale gene expression data: strategy, methods and applications","volume":"155","author":"He","year":"2023","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.apsb.2023.08.010_bib109","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.2174\/0929867327666200812215852","article-title":"Drug repurposing: a strategy for discovering inhibitors against emerging viral infections","volume":"28","author":"Dos Santos Nascimento","year":"2021","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/1566524020666200619125404","article-title":"Harnessing drug repurposing for exploration of new diseases: an insight to strategies and case studies","volume":"21","author":"Jain","year":"2021","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.apsb.2023.08.010_bib111","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug repurposing for rare diseases","volume":"42","author":"Roessler","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2023.08.010_bib112","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2174\/0929867327666200831141337","article-title":"Perspectives on drug repurposing","volume":"28","author":"Schcolnik-Cabrera","year":"2021","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib113","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2023.08.010_bib114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/0717-6287-47-27","article-title":"Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy","volume":"47","author":"Rosas","year":"2014","journal-title":"Biol Res"},{"key":"10.1016\/j.apsb.2023.08.010_bib115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.intimp.2019.01.014","article-title":"Highly aggressive plasmablastic neoplasms in patients with rheumatoid arthritis treated with methotrexate","volume":"68","author":"Tabata","year":"2019","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.apsb.2023.08.010_bib116","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/biomedicines10071589","article-title":"Drug repurposing: the mechanisms and signaling pathways of anti-cancer effects of anesthetics","volume":"10","author":"Wu","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.apsb.2023.08.010_bib117","doi-asserted-by":"crossref","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2023.08.010_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104751","article-title":"Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy","volume":"176","author":"Mifsud","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2023.08.010_bib119","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.02335-12","article-title":"Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus","volume":"57","author":"Lejal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2023.08.010_bib120","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.celrep.2019.04.053","article-title":"Naproxen exhibits broad anti-influenza virus activity in mice by impeding viral nucleoprotein nuclear export","volume":"27","author":"Zheng","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2023.08.010_bib121","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1038\/s41598-021-88886-1","article-title":"Inhibitory effects of aprotinin on influenza A and B viruses in\u00a0vitro and in\u00a0vivo","volume":"11","author":"Song","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2023.08.010_bib122","article-title":"Targeted degradation of structured RNAs via ribonuclease-targeting chimeras (RiboTacs)","volume":"18","author":"Haj-Yahia","year":"2023","journal-title":"Expet Opin Drug Discov"},{"key":"10.1016\/j.apsb.2023.08.010_bib123","doi-asserted-by":"crossref","first-page":"8832","DOI":"10.1039\/D2CS00624C","article-title":"Emerging degrader technologies engaging lysosomal pathways","volume":"51","author":"Ding","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2023.08.010_bib124","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/prot.21431","article-title":"Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease","volume":"68","author":"Chellappan","year":"2007","journal-title":"Proteins"},{"key":"10.1016\/j.apsb.2023.08.010_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2022.102344","article-title":"Recent advances in predicting protein-protein interactions with the aid of artificial intelligence algorithms","volume":"73","author":"Li","year":"2022","journal-title":"Curr Opin Struct Biol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523003064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523003064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:02:21Z","timestamp":1761930141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383523003064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":125,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2211383523003064"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2023.08.010","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging drug design strategies in anti-influenza drug discovery","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}